Trial Outcomes & Findings for CoolSculpting the Upper Arm Study (NCT NCT02669329)

NCT ID: NCT02669329

Last Updated: 2021-11-04

Results Overview

Change in the treated vs. untreated areas will be assessed by observation of changes in surface contour and/or fat volume by an independent photo review of pre-treatment and post-treatment images of the treated areas. The review panel will consist of practicing dermatologists or plastic surgeons. All reviewers will be blinded to post-treatment vs. baseline untreated area. The order in which images will be presented will be randomized; for each subject placement of the baseline, pre-treatment image will be randomized for each pair of subject images. Reviewers will be asked to select the baseline photos for each subject photo series and record selections on a data collection form. Correct identification of photos by at least 2 of the 3 reviewers has an expected success rate of 75%.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

30 participants

Primary outcome timeframe

12 weeks post treatment

Results posted on

2021-11-04

Participant Flow

Unit of analysis: arms

Participant milestones

Participant milestones
Measure
Upper Arm Treatment Group
Each subject in the arm received bilateral treatment with the CoolSculpting device. Each arm was treated once.
Overall Study
STARTED
30 60
Overall Study
COMPLETED
30 60
Overall Study
NOT COMPLETED
0 0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

CoolSculpting the Upper Arm Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Upper Arm Treatment With Vacuum Applicator
n=30 Participants
The CoolSculpting device with vacuum applicator will be used to administer treatment.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
30 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Age, Continuous
45.7 years
n=5 Participants
Sex: Female, Male
Female
30 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
Race/Ethnicity, Customized
African American
0 Participants
n=5 Participants
Race/Ethnicity, Customized
Asian
1 Participants
n=5 Participants
Race/Ethnicity, Customized
Caucasian
24 Participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic
0 Participants
n=5 Participants
Race/Ethnicity, Customized
Others
5 Participants
n=5 Participants
Region of Enrollment
Canada
30 Participants
n=5 Participants
Body Mass Index
28.2 kg//m^2
n=5 Participants

PRIMARY outcome

Timeframe: 12 weeks post treatment

Population: Thirty subjects received bilateral treatments to the upper arms. Three subjects did not maintain weight per-protocol requirements and were excluded from the primary efficacy analysis.

Change in the treated vs. untreated areas will be assessed by observation of changes in surface contour and/or fat volume by an independent photo review of pre-treatment and post-treatment images of the treated areas. The review panel will consist of practicing dermatologists or plastic surgeons. All reviewers will be blinded to post-treatment vs. baseline untreated area. The order in which images will be presented will be randomized; for each subject placement of the baseline, pre-treatment image will be randomized for each pair of subject images. Reviewers will be asked to select the baseline photos for each subject photo series and record selections on a data collection form. Correct identification of photos by at least 2 of the 3 reviewers has an expected success rate of 75%.

Outcome measures

Outcome measures
Measure
Upper Arm Treatment With Vacuum Applicator
n=54 photo pairs reviewed
The CoolSculpting device with vacuum applicator will be used to administer treatment.
Percentage of Pre-treatment Images Correctly Identified
85.2 percent correctly identified images
Interval 72.9 to 93.4

PRIMARY outcome

Timeframe: 12 weeks post-treatment

Population: The analysis population consisted of subjects to whom treatment was administered and who completed the 12 week post-treatment visit.

The incidence of reported unanticipated adverse device effects (UADE) from the time of enrollment through the 12-week follow-up visit will be collected and analyzed. It is expected there will be zero UADE's reported.

Outcome measures

Outcome measures
Measure
Upper Arm Treatment With Vacuum Applicator
n=30 Participants
The CoolSculpting device with vacuum applicator will be used to administer treatment.
Safety of the CoolSculpting Device in Upper Arm Treatments
0 UADEs reported

Adverse Events

Upper Arm Treatment With Vacuum Applicator

Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Upper Arm Treatment With Vacuum Applicator
n=30 participants at risk
The CoolSculpting device with vacuum applicator will be used to administer treatment.
Nervous system disorders
Prolonged bilateral numbness
10.0%
3/30 • Number of events 6 • Enrollment through the 12 week follow-up visit.
Nervous system disorders
Tingling outside of treatment area
3.3%
1/30 • Number of events 1 • Enrollment through the 12 week follow-up visit.
Skin and subcutaneous tissue disorders
Erythema
3.3%
1/30 • Number of events 2 • Enrollment through the 12 week follow-up visit.
Skin and subcutaneous tissue disorders
Prolonged unilateral numbness
3.3%
1/30 • Number of events 1 • Enrollment through the 12 week follow-up visit.
Skin and subcutaneous tissue disorders
Numbness
3.3%
1/30 • Number of events 1 • Enrollment through the 12 week follow-up visit.
General disorders
Stomach flu
3.3%
1/30 • Number of events 1 • Enrollment through the 12 week follow-up visit.
General disorders
Cold symptoms
6.7%
2/30 • Number of events 2 • Enrollment through the 12 week follow-up visit.

Additional Information

Kerrie Jiang, Executive Director, Regulatory, Clinical and Medical Affairs

Zeltiq Aesthetics

Phone: (925) 621-7462

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place